CURE

Global X S&P Biotech ETF

1 day chart

About CURE

Global X S&P Biotech ETF (CURE, formerly ETFS S&P Biotech ETF) is an exchange traded fund that provides exposure to U.S. healthcare biotechnology companies. These companies are engaged in the research, development and manufacturing of products based on genetic analysis and genetic engineering.

Buy Australian shares starting with CURE. Invest today with a CHESS-sponsored investing platform!

Sector

CEO

Industry

Website

globalxetfs.com.au

Market Capitalisation

$35M

Price-earnings ratio

5.28

Dividend yield

0.00%

High today

$39.30

Low today

$38.50

Open price

$38.50

52-week high

$45.69

52-week low

$37.49

Announcements

CURE FAQs

Can I buy CURE shares through Stake, an investing platform like CommSec, Selfwealth or Superhero?

Yes, the Stake platform allows you to buy CURE shares and over 8,000 stocks and ETFs across the ASX and Wall St.

How much is one share of Global X S&P Biotech ETF?

One share of Global X S&P Biotech ETF is valued at $39.20.

What is the ticker symbol for Global X S&P Biotech ETF?

The ticker symbol for Global X S&P Biotech ETF is CURE.

How do I buy CURE shares in Australia?

To buy CURE stocks in Australia you'll need to open an account with an investing platform like Stake.
To do so follow these steps:

Sign up in minutes, all you need is some I.D.
Choose Stake AUS
Deposit directly into your Stake wallet and you're ready to invest in CURE

What is the 52-week high for Global X S&P Biotech ETF stock?

The Global X S&P Biotech ETF 52-week high stock price is $45.69.

What is the 52-week low for Global X S&P Biotech ETF stock?

The Global X S&P Biotech ETF 52-week low stock price is $37.49.

What is the market capitalisation of Global X S&P Biotech ETF CURE?

As of 27/09/2023 Global X S&P Biotech ETF has a market cap of $35M.

Related Stocks

This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.